乙酰半胱氨酸纳米微球药动学及药效学评价

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (2): 136-141.

乙酰半胱氨酸纳米微球药动学及药效学评价

王福根, 庄让笑, 沈益琴, 方红英, 席建军

浙江中医药大学附属西溪医院,杭州 310023,浙江

收稿日期:2012-08-20 修回日期:2012-08-20 发布日期:2013-02-28
作者简介:王福根,男,硕士,副主任药师,研究方向:肝病药物的研发和基础研究。 Tel: 0571-85463955 E-mail: wfg85463955@126.com
基金资助:
浙江省医药卫生科技计划项目(2009A170); 杭州市医药卫生科技计划项目(2009A023)

Evaluation of pharmacokinetics and pharmacodynamics of acetylcysteine nanospheres in mice

WANG Fu-gen, SHEN Yi-qin, ZHUANG Rang-xiao, XI Jian-jun, FANG Hong-ying, XI Jian-jun

The Sixth Hospital Affiliated to Zhe Jiang University of Traditional Chinese Medicine,Hangzhou 310014, Zhejiang,China

Received:2012-08-20 Revised:2012-08-20 Published:2013-02-28

摘要/Abstract

摘要： 目的: 对制备乙酰半胱氨酸纳米微球进行药动学和药效学评价。方法: 尾静脉注射乙酰半胱氨酸纳米微球和乙酰半胱氨酸,不同时间检测血浆和各脏器的乙酰半胱氨酸。通过皮下注射CCl₄建立大鼠肝损伤模型,不同剂量乙酰半胱氨酸纳米微球进行治疗,检测血清学指标和肝组织各项指标评价纳米微球治疗慢性肝损伤的疗效。结果: 乙酰半胱氨酸纳米微球改变了药物在体内的分布,肝组织中药物浓度明显提高,半衰期显著增加。药效实验显示,纳米微球能降低血清学指标,提高肝组织抗氧化功能,减轻肝细胞脂肪变性、细胞浸润和坏死。结论: 乙酰半胱氨酸纳米微球具有明显肝靶向性,有利于肝损伤的药物治疗,是一种比较理想的乙酰半胱氨酸新剂型。

关键词: 乙酰半胱氨酸, 纳米微球, 药动学, 药效学

Abstract: AIM: To evaluate the pharmacokinetics and pharmacodynamics of acetylcysteine nanospheres. METHODS: Two groups of NAC nanoparticles and free drug groups were injected into mouse tail vein. NAC was detected in plasma and different organs at different time. Chronic liver injury model was established by subcutaneous injection of carbon tetrachloride in rats. Different doses of NAC nanoparticles were administrated.Treatment of NAC nanospheres efficacy was evaluated on serum markers and indicators of liver tissue.RESULTS: Acetylcysteine nanospheres changed the distribution of drugs in the body.The results showed that drug concentration significantly increased in the liver tissue,half-life increased obviously. Pharmacodynamics result showed that the nanospheres can reduce serum markers and improve hepatic antioxidant function.Liver biopsy showed that the nanosphere treatment groups ameliorated hepatic steatosis, inflammatory and necrosis.CONCLUSION: The acetylcysteine nanosphere had obvious liver targeting, improving therapy for liver injure. Nanospheres are an ideal new formulations for acetylcysteine.

Key words: Acetylcysteine, Nanospheres, Pharmacokinetics, Pharmacodynamics

中图分类号:

R969.1

王福根, 庄让笑, 沈益琴, 方红英, 席建军. 乙酰半胱氨酸纳米微球药动学及药效学评价[J]. 中国临床药理学与治疗学, 2013, 18(2): 136-141.

WANG Fu-gen, SHEN Yi-qin, ZHUANG Rang-xiao, XI Jian-jun, FANG Hong-ying, XI Jian-jun. Evaluation of pharmacokinetics and pharmacodynamics of acetylcysteine nanospheres in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 136-141.

参考文献

[1] Baniasadi S,Eftekhari P,Tabarsi P,et al.Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity[J].Eur J Gastroenterol Hepatol,2010, 22(10):1235-1238.
[2] 何键军,黄昉.静脉注射乙酸半胱氨酸治疗慢性重型病毒性肝炎的临床观察[J].中国现代应用药学,2000,4:327-329.
[3] 潘红英,娄国强,童永喜,等.N-乙酞半胱氨酸对重型肝炎患者白细胞介素18的影响[J].中华肝脏病杂志,2003,11:656.
[4] 姚倩,侯世祥,卢懿,等.白藜芦醇壳聚糖纳米粒的制备及理化性质[J].中国药学杂志,2009,44(6):444-447.
[5] Amini M, Zarghi A, Vatanpour H.Sensitive high-performance liquid chromatograph-ic method for determination of captopril in plasma[J].Pharmaceutica Acta Helvetiae, 1999,73(6):303-307.
[6] Galaris D,Barbouti A,Korantzopoulos P.Oxidative stress in hepatic ischemia reperfusion injury:the role of antioxidants and iron chelating compounds[J].Curr Pharm Des,2006,12(23):2875-2890.
[7] Pan M, Cederbaum AI,Zhang YL,et al.Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production[J].J Clin Invest, 2004, 113(9):1277-1287.
[8] Lavine JE.Vitamin E treatment of nonalcoholic steatohepatitis in children: a pliot study[J]. J Pediatr, 2000, 136(6):734-738.
[9] Batkai S,Mukhopadhyay P,Horvath B,et al.Delta(8)-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB(2)receptors[J].Br J Pharmacol, 2012,165(8): 2450-2461.
[10] 王福根,庄让笑,方红英,等.岩柏草总黄酮抗大鼠肝纤维化的实验研究[J].中国临床药理学与治疗学杂志,2011,16(4):371-373.
[11] Dillioglugil MO,Kir HM,Demir C, et al.Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels and SOD activities in rat liver and kidney tissues[J]. Brain Res Bull, 2010,83(6):356-359.
[12] 王福根,俞佳,席建军.乙酰半胱氨酸对大鼠酒精性肝损伤的保护作用[J].中国临床药理学与治疗学,2008,13(5):517-520.
[13] Yuzhalin AE,Kutikhin AG.Inherited variations in the SOD and GPX gene families and cancer risk[J]. Free Radical Res, 2012,46(5):581-599.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[3]	燕强勇, 向大雄, 朱荣华, 杨玲凤, 阳喜定, 李晶晶, 范晓, 刘赛, 熊守军, 方平飞. 盐酸西那卡塞片在中国健康人群的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 171-177.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	李雪静, 江金平, 李思凝, 万林飞, 周响响, 杨梿, 兰轲. 一项在中国精神分裂症受试者中评估氯氮平片的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1121-1130.
[6]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[7]	徐俪颖王淑华张高松黄继汉黄小民. 和胃止泻胶囊治疗腹泻患者的临床疗效和模型化评价[J]. 中国临床药理学与治疗学, 2022, 27(1): 47-55.
[8]	贾元威, 沈杰, 储冀汝, 张翠锋, 谢海棠, 杨斌, 李相鸿, 郑丹丹, 赵静惠. 豆腐果苷及其代谢产物时辰药动学研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 986-994.
[9]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[10]	徐国防, 高盼, 刘平, 赖耀文, 李广辉, 赵岳, 张永玲, 李晓苏, 齐琦. 肿瘤患者个体差异对卡培他滨药物代谢动力学影响[J]. 中国临床药理学与治疗学, 2021, 26(3): 305-311.
[11]	章思亮, 胡琳璘, 邵华, 陈西敬. 性别差异对精神药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(3): 324-331.
[12]	张苗, 刘倩, 么雪婷, 刘东阳. 基于口服吸收生理药动学模型的创新药早期临床食物影响研究探索[J]. 中国临床药理学与治疗学, 2021, 26(12): 1426-1429.
[13]	焦正, 李新刚, 尚德为, 董婧, 左笑丛, 陈冰, 刘剑敏, 潘雁, 周田彦, 张菁, 刘东阳, 李禄金, 方翼, 马广立, 丁俊杰, 赵维, 陈锐, 相小强, 王玉珠, 高建军, 谢海棠, 胡蓓, 郑青山. 模型引导的精准用药：中国专家共识（2021版）[J]. 中国临床药理学与治疗学, 2021, 26(11): 1215-1228.
[14]	李文超, 白向荣, 李晓玲, 姜德春. 替加环素在治疗感染性疾病中的群体药代动力学/药效学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(11): 1265-1272.
[15]	郭仙忠, 林荣芳, 林玮玮. 基于群体药动学模型的万古霉素个体化给药软件研制及应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 30-39.